Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Pulmonary rehabilitation is initiated and completed by a greater proportion of patients with IPF vs COPD or other chronic respiratory disorders.

Chinese scientists have developed a novel nanotherapy known as biomimetic extracellular vesicle spherical nucleic acids ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of ...

A new study published in the journal of Respiratory Medicine showed that a lower cumulative start rate of anti-fibrotic ...

The secrets of idiopathic pulmonary fibrosis (IPF) are written in its very name. Idiopathic refers to a disease of unknown ...

Idiopathic Pulmonary Fibrosis (IPF) is a fatal lung condition that impacts more men than women. Early detection and care can help manage this progressive disease.

Both are capable of affecting the lungs and sharing similar symptoms such as cough and shortness of breath but knowing their ...

DelveInsight's NADPH Oxidase (NOX)-Replacement Therapies Market Size, Target Population, Competitive Landscape & Market ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...